While relatives who remained clinically unaffected also had lower rates of meeting immunologic criteria (36%) or being ANA positive (64%) compared to relatives who developed ILE (62% and 97%, respectively) or transitioned to SLE (55% and 96%, respectively) at follow-up in the LAUREL cohort (p≤0.0451, Table 4), they were also significantly higher than matched, unaffected HC, with 18% frequency in meeting immunologic criteria and ANA positivity (p≤0.0061, Table 4). This evidence concerns the gene BTG3 and systemic lupus erythematosus.